NEW YORK (TheStreet) -- RATINGS CHANGES
AbbVie(ABBV) - Get Report was downgraded at Morgan Stanley to equal-weight from overweight. Twelve-month price target is $72. Stock is already pricing in potential for Hepatitis-C and Humira, Morgan Stanley said.
Advisory Board (ABCO) was upgraded at Stifel Nicolaus to buy from hold. Twelve-month price target is $47. Royall purchase should boost margins, Stifel Nicolaus said.
Ariad (ARIA) was downgraded at Credit Suisse to underperform from neutral. Twelve-month price target is $6. Launch metrics remain weak and any pricing benefit will likely be temporary, Credit Suisse said.
Macerich(MAC) - Get Report was downgraded at Deutsche Bank to hold from buy. Stock has run following disclosure of Simon Property Group(SPG) - Get Report stake in company and appears fairly valued at a 4.6% implied cap rate, Deutsche Bank said.
Toll Brothers(TOL) - Get Report was downgraded at RBC Capital to underperform from sector perform. Twelve-month price target is $30. Company has limited pricing power and will likely grow slower than its peers, RBC Capital said.
Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes," which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.